Пређи на садржај

Kvetijapin — разлика између измена

С Википедије, слободне енциклопедије
Садржај обрисан Садржај додат
м Бот: по захтеву Вукса (lat)
 
(Нису приказане 44 међуизмене 15 корисника)
Ред 22: Ред 22:


<!--Identifiers-->
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|}}
| CAS_number_Ref = {{cascite|correct|}}
| CAS_number = 111974-69-7
| CAS_number = 111974-69-7
Ред 46: Ред 45:
| molecular_weight = 383,5099 -{g/mol}-
| molecular_weight = 383,5099 -{g/mol}-
| smiles = N\1=C(\c3c(Sc2c/1cccc2)cccc3)N4CCN(CCOCCO)CC4
| smiles = N\1=C(\c3c(Sc2c/1cccc2)cccc3)N4CCN(CCOCCO)CC4
| InChI = 1/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
| StdInChI = 1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
Ред 52: Ред 50:
| StdInChIKey = URKOMYMAXPYINW-UHFFFAOYSA-N
| StdInChIKey = URKOMYMAXPYINW-UHFFFAOYSA-N
}}
}}
'''Kvetiapin''' (''Serokvel'', ''Ketipinor'') je [[atipični antipsihotik]] koji je odorobren za lečenje [[šizofrenija|šizofrenije]], [[Манично-депресивна психоза|bipolarnog poremećaja]] i kao dodatni tretman za [[Klinička depresija|depresiju]].
'''Kvetijapin''' (''Serokvel'', ''Ketipinor'') je [[atipični antipsihotik]] koji je odorobren za lečenje [[šizofrenija|šizofrenije]], [[Манично-депресивна психоза|bipolarnog poremećaja]] i kao dodatni tretman za [[Klinička depresija|depresiju]].


Godišnja prodaja ovog leka je vredna oko -{USD}- $5,7 milijardi globalno, do čega je $2.9 milijardi u SAD-u.<ref>-{[http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=SEROQUEL Details for Seroquel]}-</ref> Američki patent,<ref>-{[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288 Patent Document, U.S. Patent and Trademark Office]}-</ref> je trebalo da istekne [[2011]], ali je njegov vek produžen radi pedijatrijske ekskluzivnosti do marta [[2012]].<ref>[http://money.usnews.com/money/blogs/the-best-life/2011/04/29/blockbuster-drugs-that-will-go-generic-soon -{Blockbuster Drugs That Will Go Generic Soon}-]</ref><ref>-{[http://drugpatentwatch.com/ultimate/preview/patent/index.php?query=4879288 Seroquel patent expiration]}-</ref><ref>{{cite web |url=http://www.theodora.com/drugs/quepin_tablets_specifar.html |title=Quepin Full Prescribing Information in Drug Reference Encyclopedia |work= |accessdate=2010-04-03}}</ref>
Godišnja prodaja ovog leka je vredna oko -{USD}- $5,7 milijardi globalno, od čega je $2,9 milijardi u SAD-u.<ref>-{[http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=SEROQUEL Details for Seroquel]}-</ref> Američki patent,<ref>-{[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288 Patent Document, U.S. Patent and Trademark Office] {{Wayback|url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288 |date=20170106145854 }}}-</ref> je trebalo da istekne [[2011]], ali je njegov vek produžen radi pedijatrijske ekskluzivnosti do marta [[2012]].<ref>[http://money.usnews.com/money/blogs/the-best-life/2011/04/29/blockbuster-drugs-that-will-go-generic-soon -{Blockbuster Drugs That Will Go Generic Soon}-]</ref><ref>-{[http://drugpatentwatch.com/ultimate/preview/patent/index.php?query=4879288 Seroquel patent expiration]}-</ref><ref>{{cite web |url=http://www.theodora.com/drugs/quepin_tablets_specifar.html |title=Quepin Full Prescribing Information in Drug Reference Encyclopedia |work= |accessdate = 3. 4. 2010.}}</ref>


==Farmakologija==
== Farmakologija ==
{| class="wikitable" align="right"
{| class="wikitable" align="right"
|+ Poređenje afiniteta (-{Ki, nM}-)<ref name="dailymed PI">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41375#section-15.2 |title=SEROQUEL (quetiapine fumarate) tablet, extended release |author=AstraZeneca Pharmaceuticals LP |year=2011 |month=March |work=DailyMed |publisher=National Library of Medicine |at=Section 12.2: Pharmacodynamics |accessdate=2011-04-26}}</ref>
|+ Poređenje afiniteta (-{Ki, nM}-)<ref name="dailymed PI">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41375#section-15.2 |title=SEROQUEL (quetiapine fumarate) tablet, extended release |author=AstraZeneca Pharmaceuticals LP |year=2011 |work=DailyMed |publisher=National Library of Medicine |at=Section 12.2: Pharmacodynamics |accessdate = 26. 4. 2011.}}</ref>
! scope="col" | Receptor
! scope="col" | Receptor
! scope="col" | Kvetiapin
! scope="col" | Kvetijapin
! scope="col" | Norkvetiapin
! scope="col" | Norkvetijapin
|-
|-
| D<sub>1</sub> || 428 || 99.8
| D<sub>1</sub> || 428 || 99.8
Ред 69: Ред 67:
| 5-HT<sub>1A</sub> || 1040 || 191
| 5-HT<sub>1A</sub> || 1040 || 191
|-
|-
| <b>[[5-HT2A receptor|-{5-HT<sub>2A</sub>}-]]</b> || 38 || 2.9
| '''[[5-HT2A receptor|-{5-HT<sub>2A</sub>}-]]''' || 38 || 2.9
|-
|-
| [[Alfa-1B adrenergički receptor|&alpha;<sub>1B</sub>]] || 14.6 || 46.4
| [[Alfa-1B adrenergički receptor|&alpha;<sub>1B</sub>]] || 14.6 || 46.4
Ред 81: Ред 79:
| [[Norepinefrinski transporter|NET]] || >10000 || 34.8
| [[Norepinefrinski transporter|NET]] || >10000 || 34.8
|}
|}
Kvetiapin poseduje sledeća farmakološka dejstva:<ref name = Seroquel>{{Cite journal|author=AstraZeneca|id=276521 |title=Seroquel (quietapine fumarate) tablets |url=http://www1.astrazeneca-us.com/pi/Seroquel.pdf |format=[[Portable Document Format|PDF]]}}</ref><ref name="pmid11132243">{{cite journal | author = Richelson E, Souder T | title = Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds | journal = Life Sciences | volume = 68 | issue = 1 | pages = 29–39 | year = 2000 | month = November | pmid = 11132243 | doi = 10.1016/S0024-3205(00)00911-5| url = http://linkinghub.elsevier.com/retrieve/pii/S0024320500009115}}</ref><ref name="urlNeuropsychopharmacology: the fifth ... - Google Books">{{cite book | url = http://books.google.com/?id=BKwkonZwZD0C&pg=PA778#v=onepage&q= | title = Neuropsychopharmacology: the fifth ... - Google Books | format = | work = | accessdate = | isbn = 9780781728379 | author1 = Davis, Kenneth L | author2 = Neuropsychopharmacology, American College of | year = 2002 }}</ref><ref>http://www.drugs.com/pro/seroquel.html</ref>
Kvetijapin poseduje sledeća farmakološka dejstva:<ref name="Seroquel">{{Cite journal |author=AstraZeneca |id=276521 |title=Seroquel (quietapine fumarate) tablets |url=http://www1.astrazeneca-us.com/pi/Seroquel.pdf |format=[[Portable Document Format|PDF]] |journal= |access-date=23. 03. 2012 |archive-url=https://web.archive.org/web/20080414031803/http://www1.astrazeneca-us.com/pi/Seroquel.pdf |archive-date=14. 04. 2008 |url-status=dead |df= }}</ref><ref name="pmid11132243">{{cite journal | author = Richelson E, Souder T | title = Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds | journal = Life Sciences | volume = 68 | issue = 1 | pages = 29–39 | year = 2000 | pmid = 11132243 | doi = 10.1016/S0024-3205(00)00911-5| url = http://linkinghub.elsevier.com/retrieve/pii/S0024320500009115}}</ref><ref name="urlNeuropsychopharmacology: the fifth ... - Google Books">{{Cite book | url = http://books.google.com/?id=BKwkonZwZD0C&pg=PA778#v=onepage&q= | title = Neuropsychopharmacology: the fifth ... - Google Books | format = | work = | accessdate = |isbn=9780781728379 | author1 = Davis, Kenneth L | author2 = Neuropsychopharmacology, American College of | year = 2002 }}</ref><ref>[http://www.drugs.com/pro/seroquel.html Seroquel Official FDA information, side effects and uses{{Ботовски наслов}}]</ref>


* [[Dopaminski receptor D1|D<sub>1</sub>]] (-{IC<sub>50</sub> = 1268nM}-), [[Dopaminski receptor D2|D<sub>2</sub>]] (-{IC<sub>50</sub> = 329nM}-), [[Dopaminski receptor D3|D<sub>3</sub>]], i [[Dopaminski receptor D4|D<sub>4</sub> receptor]] [[Antagonist dopaminskog receptora|antagonist]]
* [[Dopaminski receptor D1|D<sub>1</sub>]] (-{IC<sub>50</sub> = 1268nM}-), [[Dopaminski receptor D2|D<sub>2</sub>]] (-{IC<sub>50</sub> = 329nM}-), [[Dopaminski receptor D3|D<sub>3</sub>]], i [[Dopaminski receptor D4|D<sub>4</sub> receptor]] [[Antagonist dopaminskog receptora|antagonist]]
* [[5-HT1A receptor|5-HT<sub>1A</sub>]] (-{IC<sub>50</sub> = 717nM}-), [[5-HT2A receptor|5-HT<sub>2A</sub>]] (-{IC<sub>50</sub> = 148nM}-), [[5-HT2C receptor|5-HT<sub>2C</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]] [[Serotoninski antagonist|antagonist]]
* [[5-HT1A receptor|5-HT<sub>1A</sub>]] (-{IC<sub>50</sub> = 717nM}-), [[5-HT2A receptor|5-HT<sub>2A</sub>]] (-{IC<sub>50</sub> = 148nM}-), [[5-HT2C receptor|5-HT<sub>2C</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]] [[Serotoninski antagonist|antagonist]]
* [[Alfa-1 adrenergički receptor|α<sub>1</sub>-adrenergički]] (-{IC<sub>50</sub> = 94nM}-) i [[Alfa-2 adrenergički receptor|α<sub>2</sub>-adrenergički receptor]] (-{IC<sub>50</sub> = 271nM}-) [[alfa bloker|antagonist]]
* [[Alfa-1 adrenergički receptor|α<sub>1</sub>-adrenergički]] (-{IC<sub>50</sub> = 94nM}-) i [[Alfa-2 adrenergički receptor|α<sub>2</sub>-adrenergički receptor]] (-{IC<sub>50</sub> = 271nM}-) [[alfa bloker|antagonist]]
* [[Histaminski receptor H1|-{H}-<sub>1</sub> receptor]] (-{IC<sub>50</sub> = 30nM}-) [[Антихистаминик|antagonist]]
* [[Histaminski H1 receptor|-{H}-<sub>1</sub> receptor]] (-{IC<sub>50</sub> = 30nM}-) [[Антихистаминик|antagonist]]
* [[Muskarinski acetilholinski receptor|-{mACh}- receptor]] (-{IC<sub>50</sub> = >5000nM}-) [[Muskarinski antagonist|antagonist]]
* [[Muskarinski acetilholinski receptor|-{mACh}- receptor]] (-{IC<sub>50</sub> = >5000nM}-) [[Muskarinski antagonist|antagonist]]

== Sinteza ==
Jedan od mogućih sintetičkih puteva je:<ref>-{Warawa, E. J.; Migler, B. M.; 1988, {{US Patent|4879288}}.}-</ref>

[[Датотека:Quetiapine syn.png|600px]]


== Reference ==
== Reference ==
{{reflist|2}}
{{reflist}}

== Literatura ==
* {{Cite book |ref= harv|url = http://books.google.com/?id=BKwkonZwZD0C&pg=PA778#v=onepage&q= | title = Neuropsychopharmacology: the fifth ... - Google Books | format = | work = | accessdate = |isbn=9780781728379 | author1 = Davis, Kenneth L | author2 = Neuropsychopharmacology, American College of | year = 2002 }}

== Spoljašnje veze ==

* {{cite web|publisher=The American Society of Health-System Pharmacists, Inc.|work=[[MedlinePlus]]|title=Quetiapine|date = 1. 9. 2008.|url=http://nlm.nih.gov/medlineplus/druginfo/meds/a698019.html}}
* [https://web.archive.org/web/20030925213951/http://www.nami.org/Template.cfm?Section=About_Medications&template=%2FContentManagement%2FContentDisplay.cfm&ContentID=8190 NAMI pregled]
{{-}}
{{Antipsihotici-lat}}
{{Adrenergici-lat}}
{{Holinergici-lat}}
{{Dopaminergici-lat}}
{{Serotonergici-lat}}



{{Medicinsko upozorenje-lat}}
{{Podnožje|lat=da|Medicina|Hemija}}

[[Категорија:Атипични антипсихотици]]
[[Категорија:Допамински антагонисти]]
[[Категорија:Серотонински антагонисти]]
[[Категорија:Хипнотици]]
[[Категорија:Седативи]]
[[Категорија:Пиперазини]]
[[Категорија:Дибензотиазепини]]
[[Категорија:Етри]]
[[Категорија:Алкохоли]]

Тренутна верзија на датум 7. март 2024. у 23:20

Kvetijapin
IUPAC ime
2-(2-(4-dibenzo[b,f][1,4]tiazepin- 11-il- 1-piperazinil)etoksi)etanol
Klinički podaci
Prodajno imeSerokvel
Drugs.comMonografija
MedlinePlusa698019
Kategorija trudnoće
  • US: C (Mogući rizik)
Način primeneOralnot
Pravni status
Pravni status
Farmakokinetički podaci
Bioraspoloživost9%
MetabolizamHepatički
Poluvreme eliminacije6 sata
IzlučivanjeRenalno
Identifikatori
CAS broj111974-69-7 ДаY
ATC kodN05AH04 (WHO)
PubChemCID 5002
IUPHAR/BPS50
DrugBankDB01224 ДаY
ChemSpider4827 ДаY
UNIIBGL0JSY5SI ДаY
KEGGD08456 ДаY
ChEBICHEBI:8707 ДаY
ChEMBLCHEMBL716 ДаY
Hemijski podaci
FormulaC21H25N3O2S
Molarna masa383,5099 g/mol
  • N\1=C(\c3c(Sc2c/1cccc2)cccc3)N4CCN(CCOCCO)CC4
  • InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2 ДаY
  • Key:URKOMYMAXPYINW-UHFFFAOYSA-N ДаY

Kvetijapin (Serokvel, Ketipinor) je atipični antipsihotik koji je odorobren za lečenje šizofrenije, bipolarnog poremećaja i kao dodatni tretman za depresiju.

Godišnja prodaja ovog leka je vredna oko USD $5,7 milijardi globalno, od čega je $2,9 milijardi u SAD-u.[1] Američki patent,[2] je trebalo da istekne 2011, ali je njegov vek produžen radi pedijatrijske ekskluzivnosti do marta 2012.[3][4][5]

Poređenje afiniteta (Ki, nM)[6]
Receptor Kvetijapin Norkvetijapin
D1 428 99.8
D2 626 489
5-HT1A 1040 191
5-HT2A 38 2.9
α1B 14.6 46.4
α2 617 1290
H1 4.41 1.15
M1 1086 38.3
NET >10000 34.8

Kvetijapin poseduje sledeća farmakološka dejstva:[7][8][9][10]

Jedan od mogućih sintetičkih puteva je:[11]

  1. ^ Details for Seroquel
  2. ^ Patent Document, U.S. Patent and Trademark Office Архивирано на сајту Wayback Machine (6. јануар 2017)
  3. ^ Blockbuster Drugs That Will Go Generic Soon
  4. ^ Seroquel patent expiration
  5. ^ „Quepin Full Prescribing Information in Drug Reference Encyclopedia”. Приступљено 3. 4. 2010. 
  6. ^ AstraZeneca Pharmaceuticals LP (2011). „SEROQUEL (quetiapine fumarate) tablet, extended release”. DailyMed. National Library of Medicine. Section 12.2: Pharmacodynamics. Приступљено 26. 4. 2011. 
  7. ^ AstraZeneca. „Seroquel (quietapine fumarate) tablets” (PDF). 276521. Архивирано из оригинала (PDF) 14. 04. 2008. г. Приступљено 23. 03. 2012. 
  8. ^ Richelson E, Souder T (2000). „Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds”. Life Sciences. 68 (1): 29—39. PMID 11132243. doi:10.1016/S0024-3205(00)00911-5. 
  9. ^ Davis, Kenneth L; Neuropsychopharmacology, American College of (2002). Neuropsychopharmacology: the fifth ... - Google Books. ISBN 9780781728379. 
  10. ^ Seroquel Official FDA information, side effects and uses
  11. ^ Warawa, E. J.; Migler, B. M.; 1988, U.S. Patent 4.879.288.

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).